BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eli Lilly readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Eli Lilly's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06662383-118@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:retatrutide: Phase 3 readout est. (NCT06662383)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesit
 y\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06662383
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914895-11052@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06914895)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabet
 es and Obesity or Overweight\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 14895
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962280-11052@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06962280)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Long-Term
  Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesi
 ty or Overweight\nEstimated primary completion: November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06962280
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884293-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:mazdutide: Phase 3 readout est. (NCT06884293)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study Comparing IBI362
  vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfu
 nction-associated Fatty Liver Disease （MAFLD）\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mazdutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06884293
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413706-2159@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06413706)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Glioma.\nStudy: A Study Comp
 aring Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Childre
 n and Young Adults With High-grade Glioma Following Radiotherapy\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06413706
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223840-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07223840)
DESCRIPTION:Brenipatide\, phase 2.\nStudy: A Study of Brenipatide in Adults
  Who Quit Smoking Cigarettes and Want to Avoid Relapse\nEstimated primary 
 completion: February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07223840
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672549-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672549)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Platform
  Trial for Pediatric Participants With Obesity or Overweight (LY900040)\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/orforglipron#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06672549
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215559-245@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:macupatide: Phase 2 readout est. (NCT07215559)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Study of Macupatide (
 LY3532226) and Eloralintide (LY3841136)\, Alone or in Combination\, in Adu
 lts With Obesity or Overweight and With Type 2 Diabetes\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/macupatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07215559
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269210-1093@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Solbinsiran: Phase 2 readout est. (NCT07269210)
DESCRIPTION:Solbinsiran\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study of Solbinsiran (LY3561774) in Participants With Severe Hy
 pertriglyceridemia\nEstimated primary completion: March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/solbinsiran#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07269210
URL:https://assetmemo.bio/drug/solbinsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986292-8814@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT05986292)
DESCRIPTION:LY4065967\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nSt
 udy: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-
 Appendices (ISAs) in Participants With Chronic Pain\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ly4065967#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05986292
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641504-8814@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT07641504)
DESCRIPTION:LY4065967\, phase 2.\nStudy: A Chronic Pain Master Protocol (CP
 MP): A Study of LY4065967 in Participants With Chronic Low Back Pain\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ly4065967#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07641504
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641517-8814@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT07641517)
DESCRIPTION:LY4065967\, phase 2.\nStudy: A Chronic Pain Master Protocol (CP
 MP): A Study of LY4065967 in Participants With Osteoarthritis Pain\nEstima
 ted primary completion: April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ly4065967#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07641517
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107945-308@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07107945)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps 
 Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)\
 nEstimated primary completion: 16 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07107945
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526182-1423@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06526182)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-t
 o-Severe Atopic Dermatitis\nEstimated primary completion: 25 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06526182
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186101-4@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Omvoh (mirikizumab): Phase 2 readout est. (NCT07186101)
DESCRIPTION:Omvoh (mirikizumab)\, phase 2\, Ulcerative Colitis.\nStudy: LY4
 268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderate
 ly to Severely Active Ulcerative Colitis:\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718
 6101
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999994-2013@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT05999994)
DESCRIPTION:Ramucirumab\, phase 2.\nStudy: A Master Protocol (LY900023) Tha
 t Includes Several Clinical Trials of Drugs for Children and Young Adults 
 With Cancer\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05999994
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613307-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07613307)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who
  Observe Ramadan Fasting\nEstimated primary completion: May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07613307
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338995-1423@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06338995)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3.\nStudy: A Study of Lebrikizum
 ab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyp
 s Treated With Intranasal Corticosteroids (CONTRAST-NP)\nEstimated primary
  completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lebrikizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06338995
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931028-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:mazdutide: Phase 3 readout est. (NCT06931028)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2\nEstimated p
 rimary completion: 7 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06931028
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232719-118@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:retatrutide: Phase 3 readout est. (NCT07232719)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants With Obesity or Overweight\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/retatrutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232719
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545772-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07545772)
DESCRIPTION:Brenipatide\, phase 2.\nStudy: A Study of Brenipatide (LY353703
 1) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)\nEst
 imated primary completion: July 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07545772
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285018-8814@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:LY4065967: Phase 2 readout est. (NCT07285018)
DESCRIPTION:LY4065967\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nSt
 udy: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Partic
 ipants With Diabetic Peripheral Neuropathic Pain\nEstimated primary comple
 tion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ly40
 65967#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07285018
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972459-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972459)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and a
 t Least One Weight-Related Comorbidity\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 72459
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972472-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972472)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and T
 ype 2 Diabetes\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06972472
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993792-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06993792)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Obesity or Overw
 eight With and Without Type 2 Diabetes\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 93792
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:mazdutide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:mazdutide\, phase 2\, Obesity.\nStudy: A Master Protocol Study 
 (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Pa
 rticipants With Obesity or Overweight\nEstimated primary completion: Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazdutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614
 3956
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589608-245@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:macupatide: Phase 2 readout est. (NCT07589608)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Study to Investigate 
 Weight Management With Macupatide and Eloralintide\, Alone or in Combinati
 on\, in Adult Participants With Obesity or Overweight\nEstimated primary c
 ompletion: September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/macupatide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07589608
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545759-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07545759)
DESCRIPTION:Brenipatide\, phase 2.\nStudy: A Study of Brenipatide (LY353703
 1) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)\nEstimat
 ed primary completion: September 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07545759
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948422-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948422)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Hypertension and
  Obesity or Overweight: (ATTAIN-Hypertension Screening)\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06948422
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948435-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948435)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL1\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06948435
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952530-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06952530)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL2\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06952530
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035093-118@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:retatrutide: Phase 3 readout est. (NCT07035093)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Lo
 w Back Pain\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07035093
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514054-9192@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Inluriyo (Imlunestrant): Phase 3 readout est. (NCT05514054)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant Versus Standard Endocrine Therapy in Participants With
  Early Breast Cancer\nEstimated primary completion: October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05514054
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556512-11052@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT05556512)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adu
 lts With Obesity\nEstimated primary completion: October 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05556512
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439277-11052@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06439277)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (
 SURMOUNT-ADOLESCENTS-2)\nEstimated primary completion: October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06439277
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255209-183@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:mazdutide: Phase 3 readout est. (NCT07255209)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Adolescents With Obesity or Overweight\nEstimated primary completion:
  31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maz
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07255209
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286175-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07286175)
DESCRIPTION:Brenipatide\, phase 2\, Bipolar Disorder.\nStudy: A Study of Br
 enipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07286175
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410507-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07410507)
DESCRIPTION:Brenipatide\, phase 2\, Schizophrenia.\nStudy: A Study of Breni
 patide in Adult Participants With Schizophrenia\nEstimated primary complet
 ion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 renipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07410507
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026866-664@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05026866)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's D
 isease (TRAILBLAZER-ALZ 3)\nEstimated primary completion: November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05026866
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119581-2053@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06119581)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without
  Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lu
 ng Cancer\nEstimated primary completion: November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06119581
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-2159@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07935317)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: A Stu
 dy of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Par
 ticipants With PIK3CA-Mutated Early Breast Cancer\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07935317
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735483-1423@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT05735483)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650
 150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe 
 Atopic Dermatitis\nEstimated primary completion: December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05735483
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05509777-4@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT05509777)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: A Stud
 y of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Diseas
 e\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05509777
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672939-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672939)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Adolescent Participants With Obesity\, or Ove
 rweight With Related Comorbidities\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06672
 939
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739122-127@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trulicity (dulaglutide): Phase 3 readout est. (NCT06739122)
DESCRIPTION:Trulicity (dulaglutide)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participan
 ts With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dulaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06739122
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282600-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07282600)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, and Type 2 Dia
 betes\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07282600
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721013-3359@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pirtobrutinib: Phase 1/2 readout est. (NCT06721013)
DESCRIPTION:Pirtobrutinib\, phase 1/2.\nStudy: A Study of Pirtobrutinib in 
 Participants With Immune Thrombocytopenia\nEstimated primary completion: F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06721013
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873801-1423@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT07873801)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic
  Dermatitis\nEstimated primary completion: February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07873801
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412756-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07412756)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Adult Participants With Major Depressive Disorder\nE
 stimated primary completion: February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07412756
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420283-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07420283)
DESCRIPTION:Brenipatide\, phase 2\, Opioid Use Disorder.\nStudy: A Study of
  Brenipatide in Participants With Opioid Use Disorder\nEstimated primary c
 ompletion: March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07420283
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790861-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07790861)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweig
 ht and Weight-Related Health Problems\nEstimated primary completion: March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07790
 861
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05723198-98@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT05723198)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Alopecia Areata.\nStudy: A S
 tudy of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Y
 ears of Age With Alopecia Areata\nEstimated primary completion: March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05723198
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202884-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07202884)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Female Participants With Stress Urinary Incontinence Who 
 Have Obesity or Overweight\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07202884
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321886-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07321886)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity\, or Overweight Without Type 2
  Diabetes\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07321886
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353931-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07353931)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain a
 nd Obesity or Overweight\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07353931
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369011-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07369011)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or
  Overweight\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07369011
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219173-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07219173)
DESCRIPTION:Brenipatide\, phase 2\, Asthma.\nStudy: A Study to Evaluate Bre
 nipatide Compared With Placebo in Adult Participants With Uncontrolled Mod
 erate to Severe Asthma\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/brenipatide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07219173
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153471-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07153471)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and O
 steoarthritis (OA) of the Knee\nEstimated primary completion: April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07153471
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859268-118@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:retatrutide: Phase 3 readout est. (NCT06859268)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in the Maintenance of Weight Reduction in Individuals With Ob
 esity\nEstimated primary completion: April 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06859268
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-4@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: Mir
 ikizumab Administered at the Same Time as Tirzepatide in Adult Participant
 s With Moderately to Severely Active Ulcerative Colitis and Obesity or Ove
 rweight: Phase 3b Study\nEstimated primary completion: April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219953-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07219953)
DESCRIPTION:Brenipatide\, phase 3\, Alcohol Use Disorder.\nStudy: A Study o
 f Brenipatide in Participants With Alcohol Use Disorder\nEstimated primary
  completion: April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07219953
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219966-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07219966)
DESCRIPTION:Brenipatide\, phase 3\, Alcohol Use Disorder.\nStudy: A Study o
 f Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
 \nEstimated primary completion: April 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07219966
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928245-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07928245)
DESCRIPTION:Brenipatide\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Participants With Major Depressive Disorder\nEstimat
 ed primary completion: May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07928245
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759245-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07759245)
DESCRIPTION:Brenipatide\, phase 2\, Chronic Obstructive Pulmonary Disease.\
 nStudy: A Study of Brenipatide (LY3537031) in Adult Participants With Mode
 rate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07759245
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508789-664@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05508789)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzh
 eimer's Disease (TRAILBLAZER-ALZ 5)\nEstimated primary completion: May 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05508789
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937099-4@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937099)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: Miriki
 zumab and Tirzepatide Administered in Adult Participants With Moderately t
 o Severely Active Crohn's Disease and Obesity or Overweight\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/mirikizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06937099
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223593-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07223593)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Efficacy and Safety of Orforglipron in Participants W
 ith Peripheral Artery Disease\nEstimated primary completion: June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07223593
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392190-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:eloralintide: Phase 3 readout est. (NCT07392190)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Persistent Obesity Who Are Treated Wit
 h a Weekly Incretin\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07392190
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222332-98@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07222332)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly 
 Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ba
 ricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07222332
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589595-664@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Kisunla (Donanemab): Phase 2 readout est. (NCT07589595)
DESCRIPTION:Kisunla (Donanemab)\, phase 2.\nStudy: A Study of Donanemab (LY
 3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/donanemab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07589595
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839936-1073@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:VERVE-102: Phase 2 readout est. (NCT07839936)
DESCRIPTION:VERVE-102\, phase 2\, Atherosclerotic Cardiovascular Disease.\n
 Study: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for
  Cardiovascular Disease\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/verve-102#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07839936
URL:https://assetmemo.bio/drug/verve-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542483-1423@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT07542483)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3.\nStudy: A Study of Lebrikizum
 ab in Adults With Nummular Eczema\nEstimated primary completion: August 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07542483
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226883-21@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT06226883)
DESCRIPTION:Zotemtegrast\, phase 2\, Crohn's Disease.\nStudy: A Phase 2 Stu
 dy to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zotemtegrast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06226883
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357415-118@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:retatrutide: Phase 3 readout est. (NCT07357415)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or O
 verweight\nEstimated primary completion: October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07357415
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814417-1965@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07814417)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Study of Olomorasib (LY3537982) 
 in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation\n
 Estimated primary completion: November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07814417
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213804-2607@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Sofetabart mipitecan: Phase 3 readout est. (NCT07213804)
DESCRIPTION:Sofetabart mipitecan\, phase 3\, Ovarian Cancer.\nStudy: A Thre
 e-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum
 -Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer\
 nEstimated primary completion: November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sofetabart-mipitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07213804
URL:https://assetmemo.bio/drug/sofetabart-mipitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775300-822@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07775300)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide (LY3537031) in Adult Participants With Major Depressive
  Disorder\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07775300
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287098-9192@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07287098)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Recep
 tor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2
 -) Early Breast Cancer\nEstimated primary completion: January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07287098
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383390-118@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:retatrutide: Phase 3 readout est. (NCT06383390)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: The Effect of Retatrut
 ide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults L
 iving With Obesity (TRIUMPH-Outcomes)\nEstimated primary completion: Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retatrutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 83390
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06292013-1040@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lepodisiran: Phase 3 readout est. (NCT06292013)
DESCRIPTION:Lepodisiran\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study to Investigate the Effect of Lepodisiran on the Reduction
  of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotei
 n(a) - ACCLAIM-Lp(a)\nEstimated primary completion: March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lepodisiran#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06292013
URL:https://assetmemo.bio/drug/lepodisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653153-669@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Remternetug: Phase 3 readout est. (NCT06653153)
DESCRIPTION:Remternetug\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)\
 nEstimated primary completion: April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/remternetug#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06653153
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890598-2053@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06890598)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Olomorasib (LY3537982) in Combination With Standard of Care in Partic
 ipants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung 
 Cancer\nEstimated primary completion: May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06890598
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174336-9063@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tersolisib: Phase 3 readout est. (NCT07174336)
DESCRIPTION:Tersolisib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treat
 ments in Participants With Advanced Breast Cancer With a Genetic Change (P
 IK3CA)\nEstimated primary completion: May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tersolisib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07174336
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920887-154@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:bimagrumab: Phase 2 readout est. (NCT07920887)
DESCRIPTION:bimagrumab\, phase 2.\nStudy: A Study of Bimagrumab in Particip
 ants With HFpEF\nEstimated primary completion: July 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bimagrumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07920887
URL:https://assetmemo.bio/drug/bimagrumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794579-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07794579)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Participants With Overweight at Risk of Development of Ob
 esity-Related Complications or Progression to Class 1 Obesity\nEstimated p
 rimary completion: August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/orforglipron#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07794579
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602582-664@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT07602582)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (T
 RAILBLAZER-ALZ 3-EXT).\nEstimated primary completion: September 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07602582
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881432-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:eloralintide: Phase 3 readout est. (NCT07881432)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of EloraTZP i
 n Adult Participants With Obesity Without Type 2 Diabetes\nEstimated prima
 ry completion: October 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07881432
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881458-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:eloralintide: Phase 3 readout est. (NCT07881458)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of EloraTZP i
 n Adult Participants With Obesity or Overweight and Type 2 Diabetes\nEstim
 ated primary completion: October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/eloralintide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07881458
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900633-278@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07900633)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, Type 2 Diabete
 s\, and Increased Cardiovascular Risk\nEstimated primary completion: Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eloralintid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 900633
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613294-1040@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lepodisiran: Phase 3 readout est. (NCT07613294)
DESCRIPTION:Lepodisiran\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arter
 ies of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High
  Risk\nEstimated primary completion: December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lepodisiran#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07613294
URL:https://assetmemo.bio/drug/lepodisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817875-11052@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07817875)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy\, 
 Safety\, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versu
 s Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Hav
 e Obesity (ADVANCE-SURMOUNT-KIDS)\nEstimated primary completion: December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zep
 bound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07817875
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668336-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07668336)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric P
 articipants With Type 2 Diabetes\nEstimated primary completion: March 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07668336
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571161-664@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT07571161)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: Do
 nanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpai
 red (Preclinical) Alzheimer's Disease\nEstimated primary completion: April
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07571161
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162181-3359@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07162181)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Long-Term Safety of Pirtobruti
 nib in Participants With Previously Treated Types of Blood Cancers\nEstima
 ted primary completion: May 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07162181
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415044-21@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT07415044)
DESCRIPTION:Zotemtegrast\, phase 2\, Ulcerative Colitis.\nStudy: LY4268989 
 in Adults With Moderately to Severely Active Ulcerative Colitis\nEstimated
  primary completion: June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zotemtegrast#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07415044
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-2159@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monother
 apy and in Combination With Other Antineoplastic Agents in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: July 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165028-115@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tirzepatide (Mounjaro): Phase 3 readout est. (NCT07165028)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 3.\nStudy: A Master Protocol of 
 Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic 
 Liver Disease (SYNERGY-Outcomes)\nEstimated primary completion: August 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounja
 ro#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7165028
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04844606-4@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT04844606)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A M
 aster Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Par
 ticipants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)\nEstimated
  primary completion: December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04844606
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157774-1042@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Muvalaplin: Phase 3 readout est. (NCT07157774)
DESCRIPTION:Muvalaplin\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Assessing the Impact of Muvalaplin on Major Cardiovascular Events 
 in Adults With Elevated Lipoprotein(a)\nEstimated primary completion: Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/muvalaplin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071577
 74
URL:https://assetmemo.bio/drug/muvalaplin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03773965-98@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT03773965)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idio
 pathic Arthritis\nEstimated primary completion: July 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03773965
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222137-98@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07222137)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children
  and Adults\nEstimated primary completion: July 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07222137
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241390-117@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07241390)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: A Study of Orforglipron (LY3502970) on Cardiovascular
  Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chr
 onic Kidney Disease (ATTAIN-Outcomes)\nEstimated primary completion: Augus
 t 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 1390
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
